Antimicrobial treatment challenges in the era of carbapenem resistance

Anna Maria Peri, Y. Doi, Brian A. Potoski, Patrick N.A. Harris, David L. Paterson, Elda Righi

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Infections due to carbapenem-resistant Gram-negative bacteria are burdened by high mortality and represent an urgent threat to address. Clinicians are currently at a dawn of a new era in which antibiotic resistance in Gram-negative bacilli is being dealt with by the availability of the first new antibiotics in this field for many years. Although new antibiotics have shown promising results in clinical trials, there is still uncertainty over whether their use will improve clinical outcomes in real world practice. Some observational studies have reported a survival benefit in carbapenem-resistant Enterobacteriaceae bloodstream infections using combination therapy, often including “old” antibiotics such as colistin, aminoglycosides, tigecycline, and carbapenems. These regimens, however, are linked to increased risk of antimicrobial resistance, and their efficacy has yet to be compared to new antimicrobial options. While awaiting more definitive evidence, antibiotic stewards need clear direction on how to optimize the use of old and novel antibiotic options. Furthermore, carbapenem-sparing regimens should be carefully considered as a potential tool to reduce selective antimicrobial pressure.

Original languageEnglish
Pages (from-to)413-425
Number of pages13
JournalDiagnostic Microbiology and Infectious Disease
Volume94
Issue number4
DOIs
Publication statusPublished - 08-2019

Fingerprint

Carbapenems
Anti-Bacterial Agents
Enterobacteriaceae Infections
Colistin
Aminoglycosides
Microbial Drug Resistance
Gram-Negative Bacteria
Bacillus
Uncertainty
Observational Studies
Clinical Trials
Pressure
Mortality
Infection

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Peri, Anna Maria ; Doi, Y. ; Potoski, Brian A. ; Harris, Patrick N.A. ; Paterson, David L. ; Righi, Elda. / Antimicrobial treatment challenges in the era of carbapenem resistance. In: Diagnostic Microbiology and Infectious Disease. 2019 ; Vol. 94, No. 4. pp. 413-425.
@article{37a5da40e2504582b580f144850f407c,
title = "Antimicrobial treatment challenges in the era of carbapenem resistance",
abstract = "Infections due to carbapenem-resistant Gram-negative bacteria are burdened by high mortality and represent an urgent threat to address. Clinicians are currently at a dawn of a new era in which antibiotic resistance in Gram-negative bacilli is being dealt with by the availability of the first new antibiotics in this field for many years. Although new antibiotics have shown promising results in clinical trials, there is still uncertainty over whether their use will improve clinical outcomes in real world practice. Some observational studies have reported a survival benefit in carbapenem-resistant Enterobacteriaceae bloodstream infections using combination therapy, often including “old” antibiotics such as colistin, aminoglycosides, tigecycline, and carbapenems. These regimens, however, are linked to increased risk of antimicrobial resistance, and their efficacy has yet to be compared to new antimicrobial options. While awaiting more definitive evidence, antibiotic stewards need clear direction on how to optimize the use of old and novel antibiotic options. Furthermore, carbapenem-sparing regimens should be carefully considered as a potential tool to reduce selective antimicrobial pressure.",
author = "Peri, {Anna Maria} and Y. Doi and Potoski, {Brian A.} and Harris, {Patrick N.A.} and Paterson, {David L.} and Elda Righi",
year = "2019",
month = "8",
doi = "10.1016/j.diagmicrobio.2019.01.020",
language = "English",
volume = "94",
pages = "413--425",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "4",

}

Antimicrobial treatment challenges in the era of carbapenem resistance. / Peri, Anna Maria; Doi, Y.; Potoski, Brian A.; Harris, Patrick N.A.; Paterson, David L.; Righi, Elda.

In: Diagnostic Microbiology and Infectious Disease, Vol. 94, No. 4, 08.2019, p. 413-425.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Antimicrobial treatment challenges in the era of carbapenem resistance

AU - Peri, Anna Maria

AU - Doi, Y.

AU - Potoski, Brian A.

AU - Harris, Patrick N.A.

AU - Paterson, David L.

AU - Righi, Elda

PY - 2019/8

Y1 - 2019/8

N2 - Infections due to carbapenem-resistant Gram-negative bacteria are burdened by high mortality and represent an urgent threat to address. Clinicians are currently at a dawn of a new era in which antibiotic resistance in Gram-negative bacilli is being dealt with by the availability of the first new antibiotics in this field for many years. Although new antibiotics have shown promising results in clinical trials, there is still uncertainty over whether their use will improve clinical outcomes in real world practice. Some observational studies have reported a survival benefit in carbapenem-resistant Enterobacteriaceae bloodstream infections using combination therapy, often including “old” antibiotics such as colistin, aminoglycosides, tigecycline, and carbapenems. These regimens, however, are linked to increased risk of antimicrobial resistance, and their efficacy has yet to be compared to new antimicrobial options. While awaiting more definitive evidence, antibiotic stewards need clear direction on how to optimize the use of old and novel antibiotic options. Furthermore, carbapenem-sparing regimens should be carefully considered as a potential tool to reduce selective antimicrobial pressure.

AB - Infections due to carbapenem-resistant Gram-negative bacteria are burdened by high mortality and represent an urgent threat to address. Clinicians are currently at a dawn of a new era in which antibiotic resistance in Gram-negative bacilli is being dealt with by the availability of the first new antibiotics in this field for many years. Although new antibiotics have shown promising results in clinical trials, there is still uncertainty over whether their use will improve clinical outcomes in real world practice. Some observational studies have reported a survival benefit in carbapenem-resistant Enterobacteriaceae bloodstream infections using combination therapy, often including “old” antibiotics such as colistin, aminoglycosides, tigecycline, and carbapenems. These regimens, however, are linked to increased risk of antimicrobial resistance, and their efficacy has yet to be compared to new antimicrobial options. While awaiting more definitive evidence, antibiotic stewards need clear direction on how to optimize the use of old and novel antibiotic options. Furthermore, carbapenem-sparing regimens should be carefully considered as a potential tool to reduce selective antimicrobial pressure.

UR - http://www.scopus.com/inward/record.url?scp=85062144886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062144886&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2019.01.020

DO - 10.1016/j.diagmicrobio.2019.01.020

M3 - Review article

C2 - 30905487

AN - SCOPUS:85062144886

VL - 94

SP - 413

EP - 425

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 4

ER -